Ko Nakajo

Dr. Ko Nakajo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
QHQingqing Hu
Qingqing Hu
KHKuan-Chih Huang
Kuan-Chih Huang
KNKo Nakajo
Ko Nakajo
YZYongjing Zhang
Yongjing Zhang
HQHong Qiu
Hong Qiu
Treatment for lung cancer continues to rapidly evolve. Here, we describe trends in the initial treatment of adults with newly diagnosed primary non-small-cell lung cancer in Japan. This retrospective cohort study used data from JMDC Inc. Claims Database from 2015 to 2023. Adults with lung cancer, confirmed using a combination of diagnosis, treatment, or procedure codes, were enrolled. A total of 9373 patients were included, with a mean age of approximately 59 years. The median time from diagnosis to treatment initiation ranged from 38 days in patients treated surgically to 25 days in patients with distant metastases. The observed trends were a decrease in the percentage of newly diagnosed patients with distant metastases, a decline in chemotherapy use in patients with early-stage disease, and in advanced disease, a more than doubling in the use of targeted therapy, including checkpoint inhibitors, while radiotherapy and chemotherapy tended to decrease. The observed changes in treatment were driven mainly by the increased use of targeted therapies including checkpoint inhibitors and are aligned with current treatment guidelines in Japan. The observation of fewer patients with distant metastases over time possibly indicates earlier detection. Additional research is needed to understand if new therapies are being extended to older and frail patients with lung cancer in Japan.

15 July 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HLHyunJoo Lim
HyunJoo Lim
JKJu Hwan Kim
Ju Hwan Kim
BYByong Duk Ye
Byong Duk Ye
BHBin Hong
Bin Hong
BSBohyun Suh
Bohyun Suh
JSJu-Young Shin
Ju-Young Shin
Background/Aims: Although understanding real-world treatment patterns for inflammatory bowel disease (IBD) from initial diagnosis across age groups is essential, most studies focus on adult populations and advanced therapies. Methods: We conducted a descriptive study using a national healthcare database. Patients newly diagnosed with IBD between January 2014, and December 2022 were identified and classified into two groups by disease subtype: ulcerative colitis (UC) or Crohn's disease (CD). They were further stratified by age at the index date (pediatrics: <19 years, adults: ≥19 years). Then we examined patients' characteristics and overall treatment patterns. Results: A total of 60,181 individuals were identified as IBD patients with related medication use. Primarily, a younger age at diagnosis was observed among patients with CD, contributing to the predominance of CD within the pediatric population (proportion of CD patients: 71.6% in pediatrics and 24.8% in adults). Furthermore, pediatric-onset IBD was marked by a substantial burden of comorbidities (proportion of patients with ≥2 pediatric comorbidity index score: 41.7% in UC and 46.4% in CD) and a tendency toward earlier use of advanced therapies [median time to advanced treatment initiation, months (IQR): pediatrics vs. adults; 8.1 (2.7–18.9) vs. 16.9 (6.0–36.5) in UC; 4.2 (1.6–11.6) vs. 9.6 (3.0–27.3) in CD]. Secondarily, among restricted adult population with at least 1 year follow-up since first advanced agent prescription, cumulative persistence at 12 months was 76.9%−88.5% across the most recently approved agents (vedolizumab and ustekinumab). Conclusions: This study provides a comprehensive nationwide evaluation of patient characteristics and treatment patterns in adult and pediatric IBD patients in South Korea. These findings underscore the importance of tailoring treatment strategies according to disease subtype and age at diagnosis. Given that only tumor necrosis factor (TNF)-alpha inhibitors are currently approved for pediatric use and considering the emerging evidence regarding treatment persistence with newer agents, these findings may support consideration of expanding therapeutic options for pediatric patients.